Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data. (December 2018)

• Record Type: Journal Article
• Authors: Maschio, Marta; Zarabla, Alessia; Maialetti, Andrea; Marchesi, Francesco; Giannarelli, Diana; Gumenyuk, Svitlana; Pisani, Francesco; Renzi, Daniela; Galiè, Edvina; Mengarelli, Andrea
• Is Part Of: Integrative cancer therapies. Volume 17:Number 4(2018:Dec.)
• Page Start: 1115
• Page End: 1124
• Publication Date: 2018-12
• Subjects: docosahexaenoic acid -- DHA -- α-lipoic acid -- ALA -- peripheral neuropathy -- multiple myeloma -- bortezomib -- peripheral neuropathy assessment; Cancer -- Alternative treatment -- Periodicals; 616.99406
• DOI: 10.1177/1534735418803758
• Languages: English
• ISSNs: 1534-7354

Abstract

Background and Aims: Peripheral neuropathy is a common complication of chemotherapy that can induce marked disability that negatively affects the quality of life in patients with multiple myeloma (MM). The aim of this study was to prevent the onset or the worsening of peripheral neuropathy in MM patients treated with bortezomib (BTZ), using a new nutritional neuroprotective compound. We report preliminary results of 18 out of 33 patients who completed the study.Methods: We administered a tablet of Neuronorm to patients, containing docosahexaenoic acid 400 mg, α-lipoic acid 600 mg, vitamin C 60 mg, and vitamin E 10 mg bid for the whole follow-up period. Neurological visit assessment, electroneurography, and evaluation scales were performed at baseline and after 6 months.Results: At 6 months, 8 patients had no chemotherapy-induced peripheral neuropathy, while 10 patients experienced chemotherapy-induced peripheral neuropathy of grade 1 according to the Common Terminology Criteria for Adverse Events, one of them with pain. Seventeen patients did not report painful symptoms; no limitation of functional autonomy and stability in quality of life domains explored was observed.Conclusions: Our results seem to indicate that early introduction of a neuroprotective agent in our patients with MM treated with BTZ could prevent the onset or the worsening of neuropathic pain, avoiding the interruption of the therapy with BTZ, and maintaining a good functional autonomy to allow normal daily activities. Despite the limitations due to the fact that this is a preliminary study, in a small population, with short follow-up, our data seem to indicate that the nutraceutical may have some potential to be considered for a future trial.